文摘
摘要目的:确定整个大脑的关系和深部灰质萎缩与T2LV大临床护理的患者。
背景:整个大脑和深部灰质萎缩发生在更大的速率在MS患者比健康对照组和相关临床残疾比T2-lesion卷(T2LV)更强烈。萎缩可能反映了主要神经退化或损伤反应传入或传出的预测。
设计/方法:人口和疾病特点,neuroperformance测试,和病人报告结果记录从MS患者在办公室的常规检查。临床大脑核磁共振成像获得90天+ /−通过T2LV完全自动化的方法,分析了整个大脑分数(WBF)和深部灰质体积(丘脑,壳核、尾状核和海马)。斯皮尔曼相关系数是用来评估协会;意义p < 0.001。线性回归模型被用来探索预测T2LV和丘脑的体积在调整了年龄。
结果:线性回归模型的997名患者的数据,重大发现对T2LV丘脑卷(标准化回归系数(β)=−0.31,p < 0.0001), WBF (−0.28;p < 0.0001),海马体积(−0.11,p = 0.0003),和putaminal卷(−0.08,p = 0.02),但不是尾卷。WBF是丘脑的最强预测卷(β= 0.62)的贡献较小的T2LV(−0.30)和年龄(0.12);所有p < 0.0001。所有测量卷弱病人决定疾病相关的步骤,时间25脚走路,能测试挂钩。
结论:T2LV和大脑的关系/丘脑萎缩表明二级神经退化萎缩的一个重要因素。丘脑连接最大的深部灰质结构,这可能是特别容易受到神经退化和作为全球损伤的指标。
披露:Mahajan博士已经收到个人赔偿咨询、担任科学顾问委员会说,与赛诺菲安万特Genzyme或其他活动。中村博士已经收到个人赔偿咨询、担任科学顾问委员会说,与NeuroRx研究和赛诺菲安万特Genzyme或其他活动。Nakamura博士已经收到版税、许可费或合同权利支付许可费用从生原体Idec。Nakamura博士收到Idec,研究支持赛诺菲Genzyme,诺华。冯博士没有披露。博士未曾收到生原体的研究支持。莫斯博士没有披露。麦克金尼博士已经收到个人赔偿咨询、担任科学顾问委员会说,赛诺菲Genzyme和Genentech或其他活动。李医生没有披露。琼斯博士已经收到个人赔偿咨询、担任科学顾问委员会说,与西门子和Monteris或其他活动。 Dr. Lowe has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Siemens. Dr. Boissy has nothing to disclose. Dr. Conway has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Arena pharmaceuticals. Dr. Conway has received personal compensation in an editorial capacity for Neurotherapeutics. Dr. Conway has received research support from Novartis Pharmaceuticals. Dr. Fox has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allozyne, Avanir, Biogen Idec, MedDay, Novartis, Questcor, Teva Pharmaceutical Industries, and Xenoport. Dr. Fox has received research support from Biogen (clinical trial contracts) and Novartis (research study support). Dr. Rae-Grant has nothing to disclose. Dr. Rensel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Teva, Genzyme and Novartis. Dr. Rensel has received research support from Medimmune. Dr. Willis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Novartis, Ipsen. Dr. Bermel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Genentech, Novartis, Roche. Dr. Bermel has received research support from Biogen, Genentech, Roche. Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting for Alkermes, Biogen, Convelo, EMD Serono, ERT, Gossamer Bio, Mapi, Novartis, Pendopharm, and ProValuate. Dr. Cohen has received personal compensation in an editorial capacity for Multiple Sclerosis Journal – Experimental, Translational and Clinical. Dr. Cohen has received research support from Genentech, Genzyme, Mallinckrodt, Novartis. Dr. Ontaneda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genentech, Genzyme, Merck. Dr. Ontaneda has received research support from , Genentech, Sanofi Genzyme, and Novartis Pharmaceuticals.
